Scynexis Released from Investor’s Lawsuit Over Drug Recall Risk

Scynexis Inc. and top executives defeated shareholder allegations it didn’t properly disclose cross-contamination risks of an antifungal drug before a voluntary recall and 34% stock drop.

The investor leading the case won’t file an amended complaint or appeal a ruling that dismissed his most recent pleading, he and the pharmaceutical company told the US District Court for the District of New Jersey. While lead plaintiff Brian Feldman’s claims are dismissed with prejudice, investors with similar allegations can file their own lawsuits, according to the joint agreement signed by Judge Brian Martinotti on Aug. 29.

• Feldman’s complaint didn’t adequately allege statements ...